Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 01-12-2016 | Original Article

Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit

Authors: R. J. Saint, R. V. D’Elia, C. Bryant, G. C. Clark, H. S. Atkins

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2016

Abstract

Francisella tularensis is a Gram-negative intracellular bacterium that causes the disease tularemia. The disease can be fatal if left untreated and there is currently no licenced vaccine available; the identification of new therapeutic targets is therefore required. Toll-like receptors represent an interesting target for therapeutic modulation due to their essential role in generating immune responses. In this study, we analysed the in vitro expression of the key mitogen-activated protein kinases (MAPKs) p38, JNK and ERK in murine alveolar macrophages during infection with F. tularensis. The phosphorylation profile of ERK highlighted its potential as a target for therapeutic modulation and subsequently the effect of ERK manipulation was measured in a lethal intranasal F. tularensis in vivo model of infection. The selective ERK1/2 inhibitor PD0325901 was administered orally to mice either pre- or post-challenge with F. tularensis strain LVS. Both treatment regimens selectively reduced ERK expression, but only the pre-exposure treatment produced decreased bacterial burden in the spleen and liver, which correlated with a significant reduction in the pro-inflammatory cytokines IFN-γ, MCP-1, IL-6, and TNF-α. However, no overall improvements in survival were observed for treated animals in this study. ERK may represent a useful therapeutic target where selective dampening of the immune response (to control the damaging pathology seen during infection) is combined with antibiotic treatment required to eradicate bacterial infection. This combination treatment strategy has been shown to be effective in other models of tularemia.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 413:732–738CrossRefPubMed

Jin MS, Kim SE, Heo JY, Lee ME, Kim HM et al (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130:1071–1082CrossRefPubMed

Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ et al (2001) Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 69:1477–1482CrossRefPubMedPubMedCentral

Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K et al (2003) Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 119:103–108PubMed

Sandor F, Buc M (2005) Toll-like receptors. II. Distribution and pathways involved in TLR signalling. Folia Biol 51:188–197

D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC (2013) Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol 20:319–327CrossRefPubMedPubMedCentral

D’Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC (2013) Targeting the “Rising DAMP” during a Francisella tularensis infection. Antimicrob Agents Chemother. doi:10.1128/AAC.01885-12 PubMedPubMedCentral

Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC et al (2008) Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 180:7574–7581CrossRefPubMedPubMedCentral

Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y et al (2011) Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol 90:787–797CrossRefPubMedPubMedCentral

10.

Malik M, Bakshi CS, Sahay B, Shah A, Lotz SA et al (2006) Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect Immun 74:3657–3662CrossRefPubMedPubMedCentral

11.

Macela A, Stulik J, Hernychova L, Kroca M, Krocova Z et al (1996) The immune response against Francisella tularensis live vaccine strain in Lps(n) and Lps(d) mice. FEMS Immunol Med Microbiol 13:235–238CrossRefPubMed

12.

Chen WX, KuoLee R, Shen H, Busa M, Conlan JW (2004) Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb Pathog 37:185–191CrossRefPubMed

13.

Chen WX, KuoLee R, Shen H, Busa M, Conlan JW (2005) Toll-like receptor 4 (TLR4) plays a relatively minor role in murine defense against primary intradermal infection with Francisella tularensis LVS. Immunol Lett 97:151–154CrossRefPubMed

14.

Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA et al (2008) Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol 180:6885–6891CrossRefPubMedPubMedCentral

15.

Telepnev M, Golovliov I, Sjostedt A (2005) Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb Pathog 38:239–247CrossRefPubMed

16.

Hong KJ, Wickstrum JR, Yeh HW, Parmely MJ (2007) Toll-like receptor 2 controls the gamma interferon response to Francisella tularensis by mouse liver lymphocytes. Infect Immun 75:5338–5345CrossRefPubMedPubMedCentral

17.

Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ et al (2006) Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol 176:6888–6899CrossRefPubMed

18.

Cole LE, Shirey KA, Barry E, Santiago A, Rallabhandi P et al (2007) Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages. Infect Immun 75:4127–4137CrossRefPubMedPubMedCentral

19.

Thakran S, Li HF, Lavine CL, Miller MA, Bina JE et al (2008) Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR)2/TLR1 heterodimer. J Biol Chem 283:3751–3760CrossRefPubMed

20.

Ghonime MG, Mitra S, Eldomany RA, Wewers MD, Gavrilin MA (2015) Inflammasome priming is similar for francisella species that differentially induce inflammasome activation. PLoS One 10:e0127278CrossRefPubMedPubMedCentral

21.

Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM (1999) Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 162:2291–2298PubMed

22.

Pyles RB, Jezek GE, Eaves-Pyles TD (2010) Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect Immun 78:1700–1710CrossRefPubMedPubMedCentral

23.

Parsa KVL, Butchar JP, Rajaram MVS, Cremer TJ, Tridandapani S (2008) The tyrosine kinase Syk promotes phagocytosis of Francisella through the activation of Erk. Mol Immunol 45:3012–3021CrossRefPubMedPubMedCentral

24.

Rabadi SM, Sanchez BC, Varanat M, Ma Z, Catlett SV et al (2016) Antioxidant defenses of Francisella tularensis modulate macrophage function and production of proinflammatory cytokines. J Biol Chem 291:5009–5021CrossRefPubMed

25.

Zhang P, Katz J, Michalek SM (2009) Glycogen synthase kinase-3 beta (GSK3 beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Mol Immunol 46:677–687CrossRefPubMed

26.

Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320–344CrossRefPubMedPubMedCentral

27.

Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9–18CrossRefPubMed

28.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH et al (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 18:6501–6504CrossRefPubMed

29.

Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356CrossRefPubMed

30.

Klimpel GR, Eaves-Pyles T, Moen ST, Taormina J, Peterson JW et al (2008) Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 26:6874–6882CrossRefPubMedPubMedCentral

31.

Abplanalp AL, Morris IR, Parida BK, Teale JM, Berton MT (2009) TLR-dependent control of Francisella tularensis infection and host inflammatory responses. PLoS ONE 4:e7920CrossRefPubMedPubMedCentral

32.

Hrstka R, Stulik J, Vojtesek B (2005) The role of MAPK signal pathways during Francisella tularensis LVS infection-induced apoptosis in murine macrophages. Microbes Infect 7:619–625CrossRefPubMed

33.

Du K, Zheng Q, Zhou M, Zhu L, Ai B et al (2011) Chlamydial antiapoptotic activity involves activation of the Raf/MEK/ERK survival pathway. Curr Microbiol 63:341–346CrossRefPubMed

34.

Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence. FEBS J 277:2–21CrossRefPubMed

35.

Lai XH, Sjostedt A (2003) Delineation of the molecular mechanisms of Francisella tularensis-induced apoptosis in murine macrophages. Infect Immun 71:4642–4646CrossRefPubMedPubMedCentral

36.

Asim M, Chaturvedi R, Hoge S, Lewis ND, Singh K et al (2010) Helicobacter pylori induces ERK-dependent formation of a Phospho-c-Fos.c-Jun activator protein-1 complex that causes apoptosis in macrophages. J Biol Chem 285:20343–20357CrossRefPubMedPubMedCentral

37.

Cowley SC (2009) Proinflammatory cytokines in pneumonic tularemia: too much too late? J Leukoc Biol 86:469–470CrossRefPubMed

38.

Leelahavanichkul A, Bocharov AV, Kurlander R, Baranova IN, Vishnyakova TG et al (2012) Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol 188:2749–2758CrossRefPubMed

39.

Fritz DL, England MJ, Miller L, Waag DM (2014) Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B. Comp Med 64:341–350PubMedPubMedCentral

40.

Elkins KL, RhinehartJones TR, Culkin SJ, Yee D, Winegar RK (1996) Minimal requirements for murine resistance to infection with Francisella tularesis LVS. Infect Immun 64:3288–3293PubMedPubMedCentral

Title: Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit
Authors: R. J. Saint
R. V. D’Elia
C. Bryant
G. C. Clark
H. S. Atkins
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-016-2754-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011

Quantifying the associations between antibiotic exposure and resistance - a step towards personalised antibiograms

A systematic review of Fusobacterium necrophorum-positive acute tonsillitis: prevalence, methods of detection, patient characteristics, and the usefulness of the Centor score

Bloodstream infections caused by Escherichia coli producing AmpC β-lactamases: epidemiology and clinical features

The remarkably multifunctional fibronectin binding proteins of Staphylococcus aureus

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials